clinical trial · NCT03390673
To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects
Healthy VolunteersHD204Avastin
brief summary
The purpose of this study is to compare the pharmacokinetics, as well as to evaluate the safety, tolerability and immunogenicity of HD204, US-Avastin and EU-Avastin in healthy male subjects after intravenous administration of a single dose..
started
Sep 19, 2018
primary completion
Mar 13, 2019
completion
Mar 13, 2019
last updated
Jun 17, 2026
detailed description
This is a double-blind, randomized, three-arm, parallel-group, single-dose study. A total of 120 evaluable subjects are required.
official title
A Phase I, Double-blind, Randomised, Single-dose, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol